CD274 and cancer: Interestingly, drug-conjugated STM108, an antibody that is specially developed, recognizes glycosylated PD-L1 at N192 site and leads to PD-L1 internalization and degradation, inducing a potent antitumor effect as well as a bystander-killing effect on adjacent cancer cells lacking PD-L1 expression without any detectable toxicity (75).